Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson’s Disease

Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson’s Disease

Pathological protein inclusion formation and propagation are the main causes of neuronal dysfunction in diverse neurodegenerative diseases; therefore, current disease-modifying therapeutic strategies have targeted this disease protein aggregation process. Recently, we reported that peucedanocoumarin...

Full description

Bibliographic Details
Main Authors:	Heejeong Kim, Han-Joo Maeng, Ji Hun Kim, Jin-Ha Yoon, Yohan Oh, Seung-Mann Paek, Yunjong Lee
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Series:	International Journal of Molecular Sciences
Subjects:	peucedanocoumarin IV organic synthesis Parkinson’s disease pharmacokinetics α-synuclein preformed fibril dopaminergic cell loss
Online Access:	https://www.mdpi.com/1422-0067/23/15/8618

Similar Items

Alleviating toxic α-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson’s disease
by: Alysia Ross, et al.
Published: (2020-07-01)

Novel Nasal Epithelial Cell Markers of Parkinson’s Disease Identified Using Cells Treated with α-Synuclein Preformed Fibrils
by: Hyojung Kim, et al.
Published: (2020-07-01)

Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD
by: Michiyo Iba, et al.
Published: (2022-09-01)

Alpha-Synuclein Preformed Fibrils Induce Cellular Senescence in Parkinson’s Disease Models
by: Dinesh Kumar Verma, et al.
Published: (2021-07-01)

Opposing effects of β-2 and β-1 adrenergic receptor signaling on neuroinflammation and dopaminergic neuron survival in α-synuclein-mediated neurotoxicity
by: Daniel Torrente, et al.
Published: (2023-03-01)

A Novel NOX Inhibitor Treatment Attenuates Parkinson’s Disease-Related Pathology in Mouse Models
by: Anurupa A. Ghosh, et al.
Published: (2022-04-01)

Animal models of Parkinson’s disease: bridging the gap between disease hallmarks and research questions
by: Axelle Dovonou, et al.
Published: (2023-07-01)

Genetic inactivation of alpha-synuclein affects embryonic development of dopaminergic neurons of the substantia nigra, but not the ventral tegmental area, in mouse brain
by: Tatiana V. Tarasova, et al.
Published: (2018-05-01)

Single point mutations at the S129 residue of α-synuclein and their effect on structure, aggregation, and neurotoxicity
by: Esha Pandit, et al.
Published: (2023-05-01)

Synuclein Proteins in MPTP-Induced Death of Substantia Nigra Pars Compacta Dopaminergic Neurons
by: Valeria V. Goloborshcheva, et al.
Published: (2022-09-01)

VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson’s disease
by: Xi Chen, et al.
Published: (2023-08-01)

A Novel NOX Inhibitor Alleviates Parkinson’s Disease Pathology in PFF-Injected Mice
by: Kwadwo Ofori, et al.
Published: (2023-09-01)

Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson’s disease
by: Jeong-Yong Shin, et al.
Published: (2022-12-01)

Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways
by: Jun Sung Park, et al.
Published: (2023-08-01)

Infections of Cryptococcus species induce degeneration of dopaminergic neurons and accumulation of α-Synuclein in Caenorhabditis elegans
by: Thitinan Kitisin, et al.
Published: (2022-10-01)

Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson’s Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology
by: Xiaojun Diao, et al.
Published: (2021-09-01)

Monitoring α-synuclein aggregation
by: Juan Estaun-Panzano, et al.
Published: (2023-01-01)

Host-to-graft propagation of inoculated α-synuclein into transplanted human induced pluripotent stem cell-derived midbrain dopaminergic neurons
by: Serina Gima, et al.
Published: (2024-03-01)

Rapid restructurization of conformationally-distinct alpha-synuclein amyloid fibrils at an elevated temperature
by: Mantas Ziaunys, et al.
Published: (2022-09-01)

Cell Culture Media, Unlike the Presence of Insulin, Affect α-Synuclein Aggregation in Dopaminergic Neurons
by: Irena Hlushchuk, et al.
Published: (2022-04-01)

Fibril core regions in engineered α-synuclein dimer are crucial for blocking of fibril elongation
by: Celina M. Schulz, et al.
Published: (2023-01-01)

Neuron-Astrocyte Interactions in Parkinson’s Disease
by: Ikuko Miyazaki, et al.
Published: (2020-12-01)

The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
by: Line K. Skaanning, et al.
Published: (2020-08-01)

Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
by: Simona S. Ghanem, et al.
Published: (2021-06-01)

The Synucleins and the Astrocyte
by: Abigail J. Myers, et al.
Published: (2023-01-01)

Quiescent Elongation of α-Synuclein Pre-form Fibrils Under Different Solution Conditions
by: Hengxu Mao, et al.
Published: (2022-05-01)

Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation
by: Cecilia Chavarría, et al.
Published: (2022-04-01)

Inhibition of Calpain Attenuates Degeneration of Substantia Nigra Neurons in the Rotenone Rat Model of Parkinson’s Disease
by: Vandana Zaman, et al.
Published: (2022-11-01)

Modulation Effects of Fe<sup>3+</sup>, Zn<sup>2+</sup>, and Cu<sup>2+</sup> Ions on the Amyloid Fibrillation of α-Synuclein: Insights from a FTIR Investigation
by: Yan Li, et al.
Published: (2022-12-01)

Neurons with Cat’s Eyes: A Synthetic Strain of α-Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions
by: Francesca De Giorgi, et al.
Published: (2022-03-01)

Alpha‐synuclein dynamics in induced pluripotent stem cell‐derived dopaminergic neurons from a Parkinson’s disease patient (PARK4) with SNCA triplication
by: Hayato Fukusumi, et al.
Published: (2021-02-01)

Polymorphism in alpha-synuclein oligomers and its implications in toxicity under disease conditions
by: Je Min Yoo, et al.
Published: (2022-08-01)

The role of NURR1 in metabolic abnormalities of Parkinson’s disease
by: Murad Al-Nusaif, et al.
Published: (2022-06-01)

Multiplicity of α-Synuclein Aggregated Species and Their Possible Roles in Disease
by: Pablo Gracia, et al.
Published: (2020-10-01)

Recent advances in natural products targeting α-synuclein aggregation or clearance in Parkinson's disease
by: Jay Gupta, et al.
Published: (2023-12-01)

The effects of bioactive components from the rhizome of gastrodia elata blume (Tianma) on the characteristics of Parkinson’s disease
by: Changcheng Lu, et al.
Published: (2022-11-01)

S100A9 Alters the Pathway of Alpha-Synuclein Amyloid Aggregation
by: Zigmantas Toleikis, et al.
Published: (2021-07-01)

Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein
by: Ebrima Gibbs, et al.
Published: (2022-09-01)

Mutation of Tyrosine Sites in the Human Alpha-Synuclein Gene Induces Neurotoxicity in Transgenic Mice with Soluble Alpha-Synuclein Oligomer Formation
by: Louise Berkhoudt Lassen, et al.
Published: (2022-11-01)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
by: Dimitrios Anagnostou, et al.
Published: (2023-06-01)